Therapeutic strategy in the management of stage II-IV epithelial ovarian carcinoma
Citation
Tw. Sun et al., Therapeutic strategy in the management of stage II-IV epithelial ovarian carcinoma, CHIN MED J, 113(7), 2000, pp. 625-627
Categorie Soggetti
General & Internal Medicine
Journal title
CHINESE MEDICAL JOURNAL
SICI code
0366-6999(200007)113:7<625:TSITMO>2.0.ZU;2-M
Abstract
Objective To investigate the optimal time of debulking in stage II to stage
IV epithelial ovarian carcinoma, considering corresponding advantages of b
oth surgery and chemotherapy.
Methods From January 1989 to December 1996, ninety-five stage II to stage I
V ovarian cancer patients were treated under two different regimens. Group
A 76 cases (2 cases in II,stage, 4 cases in IIb stage, 5 cases in IIc, stag
e, 58 cases in IIIc stage and 7 cases in IV stage) was managed according to
a traditional surgery-chemotherapy regimen; and group B-19 cases (17 cases
in IIIc stage and 2 cases in IV stage) was managed with a chemotherapy-sur
gery-chemotherapy regimen.
Results The optimal debulking rate (no macroscopic residual or residual < 2
cm) in group A was significantly lower than in group B, being 32.9% (25/76
) and 68.4% (13/19), respectively (P < 0.001). The average survival time of
those with a residual focus > 2 cm was shorter than those with a residual
focus < 2 cm, in both groups. Sixteen out of the 51 patients with a residua
l focus > 2 cm had a second debulking operation, among whom 7 had preoperat
ive chemotherapy. All of these 7 patients had either no residuals or residu
al < 2 cm. In 9 cases without preoperative chemotherapy, the residuals were
all > 2 cm. The average survival time among these two groups were signific
antly different (P < 0.01).
Conclusion (1) For those patients in whom optimal debulking was clinically
assessed to be possible, timely operation is mandatory. (2) For those inope
rable advanced cases, chemotherapy-surgery-chemotherapy regimen is recommen
ded. (3) For those with residuals > 2 cm and were assessed to be difficult
to eradicate during second-look operation, multi-route chemotherapy ( intro
-arterial, intraperitoneal, and systematic) should be given before going on
the second debulking operation. Positive attitude and proper regimen would
offer better results. (4) A multicenter prospective study would give more
decisive conclusion.